SEC Form 4 · accession 0001193125-26-275806
Monte Rosa Therapeutics, Inc. · GLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Champoux
Officer — Chief Operating Officer
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001826457
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 17, 2026 | M | 2,176 | $3.98 | A | 64,547 | D | |
| Common Stock | Jun 17, 2026 | S | 2,176 | $19.00 | D | 62,371 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.98 | Jun 17, 2026 | M | 2,176 | D | — | Jun 3, 2034 | Common Stock | 2,176 | 33,473 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.
- F225% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.